主页 > 医学动态 >
【medical-news】不对称二甲基精氨酸水平可以独立
Information from Industry
CYMBALTA® (duloxetine HCl) -
Provides broad and rapid relief of both emotional and physical symptoms of depression in as early as 1 to 2 weeks of treatment. CYMBALTA helps patients achieve high rates of remission.
For Prescribing Information, Boxed Warning and Safety Information, and more information, click here.
Other Product InfoSites »
NEW YORK (Reuters Health) Oct 11 - Elevated levels of asymmetric dimethylarginine (ADMA) are associated with an increased risk for coronary heart disease (CHD), according to a report in the September American Heart Journal.
ADMA inhibits nitric oxide synthase, the authors explain, and ADMA plasma levels are elevated in patients with hypertension, hypercholesterolemia, type 2 diabetes, and end-stage renal disease.
Dr. Friedrich Schulze from University Hospital Hamburg-Eppendorf, Hamburg, Germany and colleagues investigated whether ADMA is a risk factor for CHD independent of traditional cardiovascular risk factors in a multicenter study involving 131 patients with CHD and 131 healthy controls.
ADMA levels were significantly higher among CHD patients (0.70 micromol/L) than among controls (0.60 micromol/L), the authors report, as were triglyceride and C-reactive protein levels.
In the overall population, ADMA plasma levels correlated with body-mass index, creatinine levels, and plasma triglyceride levels, but not with age, the results indicate.
The ADMA plasma level also tended to increase with an increasing number of classic cardiovascular risk factors, the researchers note.
In a multivariate regression model that adjusted for the biochemical factors of the patients, only ADMA level remained a significant risk marker of CHD.
In a second model, ADMA proved to be a significant independent risk marker of CHD, along with hypercholesterolemia, hypertension, diabetes, and smoking.
The authors conclude, "In the future, ADMA may become an additional biochemical parameter for clinical routine to identify those patients at higher risk for future cardiovascular events besides the traditional parameters used today."
Am Heart J 2006;152:493.e1-493.e8. 认领此篇 不对称二甲基精氨酸水平可以独立预测冠心病风险
纽约（路透社健康）10月11日：根据美国心脏期刊9月的报道，不对称二甲基精氨酸(ADMA)水平的提高与增加患冠心病风险相关。
作者解释：ADMA能抑制一氧化氮合成酶，并且在高血压、高胆固醇血症、二型糖尿病和肾病后期患者的血浆中ADMA水平增高。
德国汉堡Hamburg-Eppendorf,大学医院的Friedrich Schulze博士极其同事在一项包括131冠心病患者和131健康对照者的多中心研究中，研究了ADMA是否是独立于冠心病传统风险因子的风险因子。
作者报道了冠心病患者的ADMA水平(0.70 micromol/L)比在对照健康者的ADMA水平(0.60 micromol/L)显著增高，就象甘油三酸酯和c-反应蛋白水平一样增高。
在全部人群中，ADMA血浆水平与体重指数、肌氨酸酐水平和血浆甘油三酸酯水平相关，但与年龄、结果显示不相关。
研究者还注意到：ADMA血浆水平倾向于随着传统的心血管风险因子种类的增加而增加。
在根据患者生化因子调整的多变量回归模型研究中，只有ADMA水平仍然是冠心病的显著风险标志物。
在第二个模型中，ADMA被证明是冠心病显著的、独立的标志物，伴随高胆固醇血症、高血压、糖尿病和吸烟。
作者得出结论：“将来ADMA可能成为又一个除目前所用的传统参数以外的生化参数，用于临床常规确认那些将来可能发生心血管病的高风险的患者。”
美国心脏期刊2006;152:493.e1-493.e8
说明：前面的一段与本文无关，所以没翻。 修改及润色： 多谢sfboy战友提出了建议，其实我是学微生物的及医学遗传学的。 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-04-01 17:14
医学,生命科学网